Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-01

Clinical Trial Update: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A long-term safety study of mavrilimumab in adults with rheumatoid arthritis (Phase 2) was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mavrilimumab (mavrilimumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2017-06-01